Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

NDAQ:RIGL - Post by User

Rigel Pharmaceuticals Inc

Bullboard Posts

Next >>

Post by BudFawkson Mar 09, 2021 5:39am

123 Views

Post# 32750148

Rigel Pharmaceuticals Awarded US Patent

Stock is up in pre-market. News only on benzinga so far.
https://www.benzinga.com/news/21/03/20071260/rigel-pharmaceuticals-awarded-u-s-patent-10-941-134-ampk-activating-heterocyclic-compounds-and-metho

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading